An interventional study of Active tDCS and Aerobic exercise in Chronic Widespread Pain and Fibromyalgia (FM), sponsored by Vrije Universiteit Brussel. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by Vrije Universiteit Brussel · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Chronic Pain by Vrije Universiteit Brussel — 4 open to participants now, 4 under way, none of them phase 3. Chronic Pain · Vrije Universiteit Brussel.
Among the 16 studies in Chronic Pain by Vrije Universiteit Brussel, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is one of 8 with no phase, and was the 16th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →4 of the 16 studies in Chronic Pain by Vrije Universiteit Brussel are open now, in 2 countries. Recruiting first, the newest first:
Vrije Universiteit Brussel · Sites in Belgium
Ages 18–60 · Healthy volunteers
Vrije Universiteit Brussel · Sites in Belgium, Netherlands
Ages 18–65
Vrije Universiteit Brussel · Sites in Belgium
Ages 18+
By country, each count listing its studies:
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 120 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 57 across the 10 interventional studies, 82 across the 6 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Vrije Universiteit Brussel is the lead sponsor of 160 studies on the registry; 43 are open to participants now.
1 of the studies in Chronic Pain by Vrije Universiteit Brussel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06834724Vrije Universiteit BrusselClinical Outcomes of Continuous Positive Airway Pressure Treatment in People With Obstructive Sleep Apnea and Chronic Pain | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Chronic Pain by Vrije Universiteit Brussel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Many people with chronic widespread pain (CWP) feel more pain and fatigue after exercise. This makes it hard to stay active. Unfortunately, the investigators do not fully understand why this happens and how to prevent it.
The primary goal of this study is to explore the underlying genetic and epigenetic mechanisms of BDNF gene in response to exercise, and investigate if transcranial direct current stimulation (tDCS) during exercise works to improve worsening symptoms response to exercise in people with CWP.
The investigators designed a randomized crossover study and will enroll 60 patients with CWP and 60 healthy controls. Participants will undergo 2 interventions in random order: 1) exercise + active tDCS, and 2) exercise + sham tDCS. Participants will visit the hospital twice with at least one week in between the visits.
Many people with chronic widespread pain (CWP), such as those with fibromyalgia, experience increased pain in response to exercise, which discourages continued physical activity. Although abnormal gene expression via epigenetic mechanisms has been implicated in CWP, the underlying mechanisms by which exercise exacerbates symptoms remain unclear. DNA methylation is one way that environmental factors like exercise can alter gene expression, and brain-derived neurotrophic factor (BDNF) plays a central role in both neuroplasticity and pain processing. The investigators hypothesize that aberrant expression of the BDNF gene contributes to post-exercise symptom flares in CWP.
Transcranial direct current stimulation (tDCS) has been shown to modulate neuroplasticity and influence gene expression, making it a promising approach to normalize BDNF regulation during exercise.
In this randomized crossover trial, 60 CWP patients and 60 healthy controls will each undergo two sessions: (1) exercise with active tDCS and (2) exercise with sham tDCS. Each participant will visit the hospital twice, with at least one week between sessions. During each session, participants will receive one bout of submaximal aerobic exercise (20 min), along with a single session of active or sham tDCS (30 min) simultaneously. The order of interventions will be well-balanced and randomly allocated to each participant. We will measure pain intensity, serum BDNF protein levels, and BDNF gene methylation before and after each session. To capture longer-term effects, participants will also complete online symptom assessments at 8 hours, 24 hours, 48 hours, and 7 days post-exercise.
The primary objective of this study is to determine how active versus sham tDCS during exercise influences BDNF expression, DNA methylation patterns, and pain intensity in CWP patients.
The secondary objectives are to 1) compare these tDCS-induced changes between CWP patients and healthy controls; and 2) identify factors that influence tDCS/exercise-induced changes, including baseline BDNF levels, DNA methylation patterns, genetic polymorphisms and Lifestyle variables (e.g., physical activity).
By elucidating the epigenetic regulation of BDNF in exercise-induced pain and evaluating tDCS as a modulatory intervention, this study seeks to identify biomarkers of symptom exacerbation and develop non-pharmacological strategies that enable CWP patients to remain active without worsening their pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients
Participants in the patient group must meet all of the following criteria:
Healthy control group
Participants in the healthy control group must meet all of the following criteria:
Exclusion Criteria:
For both patients and healthy controls, participants will be excluded if they meet any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient participants will receive one bout of submaximal aerobic exercise, along with a single session of active tDCS simultaneously.
Device: Active tDCS · Behavioral: Aerobic exercise
Patient participants will receive one bout of submaximal aerobic exercise, along with a single session of sham tDCS simultaneously.
Behavioral: Aerobic exercise · Device: Sham tDCS
healthy volunteer participants will receive one bout of submaximal aerobic exercise, along with a single session of active tDCS simultaneously.
Device: Active tDCS · Behavioral: Aerobic exercise
healthy volunteer participants will receive one bout of submaximal aerobic exercise, along with a single session of sham tDCS simultaneously.
Behavioral: Aerobic exercise · Device: Sham tDCS
tDCS is performed using a monophasic current device. Pairs of silicon sponge sur-face electrodes (35 cm2) are soaked in saline and positioned as follows: the anode is placed over the region of the dorsolateral prefrontal cortex (DLPFC) per the international 10/20 system at point F3 (left DLPFC), and the cathode is placed on the contralateral supraorbital area (FP2 site). For active tDCS, the current is ramped up for 30 seconds until the center electrode reaches a target intensity of 2 mA, then remains for 29 minutes before dropping for another 30s.
Participants will perform a moderate aerobic exercise (AE, known as aerobic power index), using a cycle er-gometer. The exercise intensity is moderate and individually tailored based on each participant's estimated maximum heart rate (HRmax), calculated using the validated formula: HRmax = 211 - (0.64 × age).
tDCS is performed using a monophasic current device. Pairs of silicon sponge sur-face electrodes (35 cm2) are soaked in saline and positioned as follows: the anode is placed over the region of the dorsolateral prefrontal cortex (DLPFC) per the international 10/20 system at point F3 (left DLPFC), and the cathode is placed on the contralateral supraorbital area (FP2 site). In the sham condition, current is ramped up to 2.0 mA for 30 seconds and then ramped down to 0 mA, with the total session duration matched to the active condition. This procedure was used to mimic the tingling sensa-tions typically experienced at the beginning of stimulation. Participants received identical instructions, session timing, and room setup across conditions.
Pain intensity
Pain intensity is measured using a 0-10 Numeric Rating Scale (NRS), where 0 indicates "no pain" and 10 indicates "the worst pain imaginable".
Time frame: Participants rate their pain at baseline, and 30 minutes after the intervention.
Blood BDNF levels
Venous blood samples are collected before and after each exercise-tDCS session. Samples are centrifuged, aliquoted, and stored at -80 °C until analysis. Blood levels of brain-derived neurotrophic factor (BDNF) are quantified using a commercially available enzyme-linked immunosorbent assay (ELISA), following the manufacturer's instructions.
Time frame: Blood samples are collected at baseline and 20 minutes after exercise-tDCS session.
BDNF DNA methylation
Genomic DNA is extracted from whole blood collected at baseline and after the intervention. DNA methylation of the BDNF gene is assessed using bisulfite conversion followed by quantitative analysis of methylation levels at CpG sites within promoter regions previously associated with pain regulation. Methylation levels are expressed as the percentage of methylated cytosines at each CpG site. Changes in DNA methylation are calculated as the difference between post-intervention and baseline values.
Time frame: Blood samples are collected at baseline and 20 minutes after exercise-tDCS session.
Pain intensity
Pain intensity is measured using a 0-10 Numeric Rating Scale (NRS), where 0 indicates "no pain" and 10 indicates "the worst pain imaginable".
Time frame: Participants rate their pain at immediately, 8 hours, 24 hours, 48 hours, and 7 days after the intervention.
Fatigue
Brugmann Fatigue Scale (BFS). Fatigue is assessed with the BFS, an 8-item self-report questionnaire (4 mental and 4 physical items; each scored 0-3). Subscale scores range 0-12 (mental; physical), and the total score ranges 0-24; higher scores indicate greater fatigue/rest propensity.
Time frame: Participants rate their fatigue at baseline, and 24 hours, 48 hours, 7 days after the intervention.
Fibromyalgia symptom impact
Revised Fibromyalgia Impact Questionnaire (FIQR). The FIQR evaluates the overall impact of fibromyalgia on functioning, symptoms, and quality of life. The total score ranges 0-100 (higher = greater disease burden), comprising function (0-30), overall impact (0-20), and symptoms (0-50) after standard weighting; each item is rated 0-10.
Time frame: Participants rate their FIQR at baseline, and 7 days after intervention.
Central sensitization symptoms
The Central Sensitization Inventory (CSI) is administered to assess symptoms related to central sensitization, such as sensitivity to touch, light, or sound, sleep disturbances, and concentration difficulties. Scores range from 0 to 100, with higher scores reflecting greater symptom severity. Each item is rated 0-4.
Time frame: Participants rate their CSI at baseline.
Pain catastrophizing
The Pain Catastrophizing Scale (PCS) is used to measure catastrophic thoughts and feelings related to pain, in-cluding rumination, magnification, and helplessness. Each item is rated 0-4. Total scores range from 0 to 52, with higher values indicating stronger pain catastrophizing tendencies.
Time frame: Participants rate their PCS at baseline, and 30 minutes after the intervention.
Anxiety and depression
HADS consists of two subscales: HADS-A, designed to detect anxious states, and HADS-D, designed to detect de-pressive states. Each subscale consists of 7 items with a 4-point ordinal response format. Scores range from 0 to 21 in each subscale, with higher scores indicating higher levels of anxious or depressive state. Participants an-swer each item thinking of how they felt and/or behaved during the past week.
Time frame: Participants rate their HAD at baseline.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 22 months is close to that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.